Sun Site Stares At FDA Action But Dent May Be Limited
Executive Summary
FDA action awaits Sun’s manufacturing facility in Halol after it failed to adequately address GMP deviations, though India’s top-ranked drug firm appears to have effectively lowered its dependence on the site that has had a patchy compliance run.
You may also be interested in...
The Quality Lowdown: Pandemic Inspection Results Trickle In As Investigators Venture Out
US FDA inspections lead to warning letters for Aurobindo and Health Plus, while Emergent BioSolutions site escapes nearly unscathed; Sun waits for Halol revisit and Jubilant suffers poor-quality costs as agency investigators resume domestic surveillance post-omicron.
India Lockdown: Early Signs of Manufacturing Strains But Resolutions Underway
Pharmaceutical manufacturing in India is facing some early stress amid the new 21-day lock-down but both the industry and government machinery are actively engaged and working together to ensure that disruptions are minimized in the ‘pharmacy of the world.’
Sun Sees Urgency To Establish Low Dose Absorica In US
Sun’s key specialty asset Ilumya makes progress, albeit slowly, in the US, while the firm sees ‘short window’ to ensure that Absorica LD gains grip in that market ahead of impending arrival of generic.